scientifyRESEARCH
research funding database

RESEARCH FUNDING

This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

Real World Evidence of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis (worldwide)

Share this post

ERC webinar 2024
Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange play symbol appears between the two logos. An arrow mark points to the logos.

The Real World Evidence of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis research grant from Pfizer seeks to generate new Real World Evidence (RWE) in the management of atopic dermatitis (AD) with abrocitinib. Applications are open to researchers based in countries where abrocitinib is approved. The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy. Applicant must be affiliated with a host institution.

Applicants may apply for up to 175,000 USD for up to 9 months (including 28% indirect costs).

Applications are due on January 11, 2024.

The grant has closed Sign-up for our content alerts to be updated when it re-opens.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for the
scientifyRESEARCH
monthly funding newsletter

unsubscribe at any time